Bicycle Therapeutics reports Q4 EPS ($1.01), consensus ($1.06)

Reports Q4 revenue $3.19M, consensus $3.89M. "We have made continued clinical progress across our pipeline, including advancing BT8009 and BT5528 into the ongoing dose expansion cohorts and are encouraged by the progress of BT7480 in the ongoing dose escalation portion of its clinical trial," said Kevin Lee, CEO of Bicycle Therapeutics. "We are pleased to have a balance sheet that has supported the advancement and expansion of our clinical portfolio, with an anticipated financial runway into 2025. We believe we are well-positioned ahead of multiple potential inflection points as we pursue our goal of demonstrating the true therapeutic potential of Bicycle Toxin Conjugates(R) and Bicycle tumor-targeted immune cell agonists."